Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) is a growth-oriented biopharmaceutical company headquartered in Chicago, Illinois, focused on improving patient lives by developing and commercializing innovative, ready-to-use therapeutic medicines across multiple therapy areas. The company's marketed portfolio includes Gvoke (glucagon injection), the first FDA-approved autoinjector for severe hypoglycemia; Recorlev (levoketoconazole), a cortisol synthesis inhibitor for Cushing's syndrome; and Keveyis (dichlorphenamide), the first FDA-approved treatment for primary periodic paralysis. Xeris leverages its proprietary XeriSol and XeriJect formulation technology platforms to develop stable, ready-to-use formulations of water-insoluble compounds, enabling both new product development and life-cycle management of existing assets. The company operates as the principal subsidiary of Xeris Biopharma Holdings, Inc. with a commercial presence across the United States, Ireland, and other international markets.